Improving Transplant Outcomes with
VP.S ENCORE^®

VP.S ENCORE^® is a portable, accessible, and easy-to-use hypothermic oxygenated perfusion system in development built to address the limitations of current preservation methods.

FDA Breakthrough Device Designation

VP.S ENCORE^® is designed to advance heart transplantation by addressing key limitations in organ preservation and transport, with the goal of expanding the donor pool, improving organ-matching opportunities, and reducing the risk of graft rejection.

VP.S ENCORE^® is not yet approved for commercial use by the FDA. The findings presented below are based on preclinical and translational research and do not constitute clinical evidence of safety or efficacy.

Strong Preclinical Data for VP.S ENCORE^®

Preclinical evaluation of VP.S ENCORE^® has demonstrated encouraging results across porcine, adult human, and pediatric heart models, supporting continued evaluation of the technology for heart preservation and transplantation.

Human Data

VP.S ENCORE^® was shown to sustain viable lactate levels in human hearts for 8+ hours.

Porcine Transplant Data

VP.S ENCORE^® demonstrated functional recovery and viability in orthotopic porcine transplants.

Porcine Preclinical Data

Porcine studies illustrate absence of significant organ edema with stable lactate levels up to 24 hours with VP.S ENCORE^®.

PEDS Data

VP.S ENCORE^® Illustrates Clinical Potential for PEDS

Trusted by Industry Leaders

Dr. Marco Morales

Physician
Texas Heart Institute
Houston, TX

“Up to 65% of hearts are not viable due to problems during transport, including lack of oxygen, nutrients, or circulation. VP.S ENCORE^® changes that by supplying oxygen and nutrients at low temperatures and reducing inflammation and rejection in the recipients.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“Absent the need for the whole blood as an oxygen carrier, VP.S ENCORE^® stands out from other commercially available non-ischemic heart preservation systems. I am certain this device will dramatically change the landscape of heart transplantation.”

Dr. Bud Frazier

Cardiothoracic Surgeon and Inventor of the LVAD
Texas Heart Institute
Houston, TX

“This approach may allow for better placement as well as function of transplanted hearts. The hope is that through extended viability of the donor heart, a more precise immunologic matching may be achieved. This will result in improved long-term survival of transplants, as well as better donor utilization.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“VP.S ENCORE^® mitigates both cold and ischemic injury and safely extends the period that the organ can be preserved outside of the body. In comparison to its competitors, it provides unrivaled portability and ease of use.”

Dr. Marco Morales

Physician
Texas Heart Institute
Houston, TX

“This medical device will help to increase organ viability and therefore the organ pool available to hospitals around the United States. This will ultimately improve the long-term survival of organs for patients in need of a transplant.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“I am particularly excited for the potential of VP.S ENCORE^® to improve the outcomes of transplanting the grafts from donation after circulatory death.”

Dr. Marco Morales

Physician
Texas Heart Institute
Houston, TX

“Up to 65% of hearts are not viable due to problems during transport, including lack of oxygen, nutrients, or circulation. VP.S ENCORE^® changes that by supplying oxygen and nutrients at low temperatures and reducing inflammation and rejection in the recipients.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“Absent the need for the whole blood as an oxygen carrier, VP.S ENCORE^® stands out from other commercially available non-ischemic heart preservation systems. I am certain this device will dramatically change the landscape of heart transplantation.”

Dr. Bud Frazier

Cardiothoracic Surgeon and Inventor of the LVAD
Texas Heart Institute
Houston, TX

“This approach may allow for better placement as well as function of transplanted hearts. The hope is that through extended viability of the donor heart, a more precise immunologic matching may be achieved. This will result in improved long-term survival of transplants, as well as better donor utilization.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“VP.S ENCORE^® mitigates both cold and ischemic injury and safely extends the period that the organ can be preserved outside of the body. In comparison to its competitors, it provides unrivaled portability and ease of use.”

Dr. Marco Morales

Physician
Texas Heart Institute
Houston, TX

“This medical device will help to increase organ viability and therefore the organ pool available to hospitals around the United States. This will ultimately improve the long-term survival of organs for patients in need of a transplant.”

Dr. Marian Urban

Cardiothoracic Surgeon
University of Nebraska Medical Center
Omaha, NE

“I am particularly excited for the potential of VP.S ENCORE^® to improve the outcomes of transplanting the grafts from donation after circulatory death.”

Join VPS Clinical Trials

Help VPS advance donor organ viability by participating in an upcoming clinical trial. Please fill out the form to express your interest.

Contact Us